Novel treatments of autosomal dominant polycystic kidney disease.
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Rex L
RL
Mahnensmith
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
D065092:Antidiuretic Hormone Receptor Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013004:Somatostatin; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases
ADPKD; mTOR inhibitors; somatostatin analogs; statins; vasopressin antagonists